Recent Material Events - Gilead Science (GILD)

Filing Date	Description
2008-08-05	At a meeting held on July 30, 2008, the board of directors (the Board) of Gilead Sciences, Inc. (the Company) elected Richard J. Whitley, MD to the Board effective July 30, 2008. Dr. Whitley will serve on the Board’s Scientific Committee. The ...
2008-05-22	On May 22, 2008, John C. Martin, PhD, Chairman and Chief Executive Officer of Gilead Sciences, Inc., a Delaware corporation (the Company), entered into a new stock trading plan under Rule 10b5-1 of the Securities Exchange Act of 1934 (Rule 10b5-1). J ...
2008-05-09	On May 7, 2008, the Board of Directors (the Board) of Gilead Sciences, Inc. (the Company) appointed John F. Milligan, Ph.D. to the position of President, replacing John C. Martin, Ph.D., who will continue to serve as the Company’s Chief Executiv ...
2008-04-03	On February 18, 2008, Kristen M. Metza, Senior Vice President, Human Resources of Gilead Sciences, Inc., a Delaware corporation (the Company), entered into a stock trading plan under Rule 10b5-1 of the Securities Exchange Act of 1934 (Rule 10b5-1). J ...
2008-03-07	On March 6, 2008, Gilead Sciences Limited (GSL), one of the wholly-owned Irish subsidiaries of Gilead Sciences, Inc., a Delaware corporation, and Ampac Fine Chemicals LLC, a California limited liability company (AFC) entered into a Tenofovir Disoprox ...
2008-01-22	Effective January 17, 2008, Caroline Dorsa resigned as the Senior Vice President and Chief Financial Officer of Gilead Sciences, Inc. (the Company). Effective the same date, John F. Milligan, Ph.D., the Company's Chief Operating Officer, reassumed th ...
2007-12-19	Under the Credit Agreement, the Borrowers may borrow initially up to an aggregate of $1.25 billion in revolving credit loans. The Credit Agreement also includes a sub-facility for swing line loans and letters of credit. Loans under the Credit Agreeme ...
2007-12-13	On December 10, 2007, Gilead Sciences Limited, a wholly-owned subsidiary of Gilead Sciences, Inc. (Gilead), and Bristol-Myers Squibb Company (BMS) entered into a Commercialization Agreement, which sets forth the terms and conditions under which Gilea ...
2007-10-26	On October 22, 2007, the Board of Directors (the Board) of Gilead Sciences, Inc. (the Company) amended and restated the terms and provisions of the Company’s 2004 Equity Incentive Plan (the Restated 2004 Plan) under which shares of the Company ...
2007-10-18	Non-GAAP net income, net income per diluted share, research and development (R&D) expenses and selling, general and administrative (SG&A) expenses for the 2007 periods are presented excluding the impact of stock-based compensation expense and ...